A067630 Stock Overview
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally.
HLB Life Science Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩13,450.00|
|52 Week High||₩23,000.00|
|52 Week Low||₩9,310.00|
|1 Month Change||27.49%|
|3 Month Change||27.49%|
|1 Year Change||33.83%|
|3 Year Change||84.88%|
|5 Year Change||303.30%|
|Change since IPO||642.07%|
Recent News & Updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
While HLB Life Science Co., Ltd. ( KOSDAQ:067630 ) shareholders are probably generally happy, the stock hasn't had...
|A067630||KR Healthcare||KR Market|
Return vs Industry: A067630 exceeded the KR Healthcare industry which returned -38.5% over the past year.
Return vs Market: A067630 exceeded the KR Market which returned -14.3% over the past year.
|A067630 Average Weekly Movement||10.7%|
|Healthcare Industry Average Movement||5.7%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A067630 is more volatile than 90% of KR stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: A067630's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood.
HLB Life Science Fundamentals Summary
|A067630 fundamental statistics|
Is A067630 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A067630 income statement (TTM)|
|Cost of Revenue||₩59.15b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-514.69|
|Net Profit Margin||-91.88%|
How did A067630 perform over the long term?See historical performance and comparison
Is HLB Life Science undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A067630's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A067630's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A067630 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.
PE vs Market: A067630 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A067630's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A067630 is overvalued based on its PB Ratio (5.2x) compared to the KR Healthcare industry average (2.2x).
How is HLB Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HLB Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has HLB Life Science performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A067630 is currently unprofitable.
Growing Profit Margin: A067630 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A067630 is unprofitable, and losses have increased over the past 5 years at a rate of 52.1% per year.
Accelerating Growth: Unable to compare A067630's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A067630 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.4%).
Return on Equity
High ROE: A067630 has a negative Return on Equity (-19.99%), as it is currently unprofitable.
How is HLB Life Science's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A067630's short term assets (₩156.8B) exceed its short term liabilities (₩13.5B).
Long Term Liabilities: A067630's short term assets (₩156.8B) exceed its long term liabilities (₩10.7B).
Debt to Equity History and Analysis
Debt Level: A067630 has more cash than its total debt.
Reducing Debt: A067630's debt to equity ratio has reduced from 83.8% to 1.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A067630 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A067630 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 27.7% each year
What is HLB Life Science current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A067630's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A067630's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A067630's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A067630's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A067630 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Sung-Bo Sim serves as the Chief Executive Officer and President at HLB Life Science Co.,Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
HLB Life Science Co., Ltd.'s employee growth, exchange listings and data sources
- Name: HLB Life Science Co., Ltd.
- Ticker: A067630
- Exchange: KOSDAQ
- Founded: 1998
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: ₩1.284t
- Shares outstanding: 95.50m
- Website: https://www.hlb-ls.com
Number of Employees
- HLB Life Science Co., Ltd.
- 51-9, Dongtancheomdansaneop 1-ro
- 8th Floor
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/13 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.